Dominari Announces Strategic Entry into U.S. AI Data Center Market
- Special Cash Dividend Determined to be $0.32 per Share. NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company" or "Dominari") today announced the creation of American Data Centers Inc. ("ADC").
- 02/18/2025
|
Dominari Holdings Inc. Announces $13.5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules and Declares Special Cash Dividend
- NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Dominari Holdings Inc. (NASDAQ:DOMH) (the "Company" or "Dominari") today announced that it has entered into definitive securities purchase agreements with certain investors for 1,439,467 shares of its common stock, Series A warrants ("Series A Warrants") to purchase up to 1,439,467 shares of common stock and Series B warrants ("Series B Warrants", together with the Series A Warrants, the "Warrants") to purchase up to 1,439,467 shares of common stock at a combined purchase price of $3.47 per share and accompanying Warrants in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Dominari also agreed to issue and sell 2,436,587 shares of common stock, Series A Warrants to purchase up to 2,436,587 shares of common stock and Series B Warrants to purchase up to 2,436,587 shares of common stock at the same purchase price as in the registered direct offering.
- 02/11/2025
|
Dominari Holdings Inc. Strengthens Team with Appointment of Experienced Accounting Team
- Edward Deignan Appointed as VP of Finance and Accounting Kyle Degruttola Appointed as Controller NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today announced that it has appointed Edward Deignan as Vice President of Finance and Accounting and Kyle Degruttola as Controller. Together, they bring decades of accounting and finance leadership experience from various multi-national and public sector organizations.
- 11/11/2024
|
Dominari Securities LLC Announces Appointment of Capital Markets Veteran James Hopkins as Managing Director Head of Capital Markets
- Hopkins has Led and Structured Hundreds of Capital Markets Transactions NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today noted that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"), announced that it has further expanded its practice with the appointment of capital markets veteran James (Jimmy) Hopkins as Managing Director Head of Capital Markets. Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "Our commitment to positioning Dominari as a full-service, diversified financial services firm and growing our business remains stronger than ever, and Jimmy has a proven record of success with hundreds of completed transactions.
- 10/07/2024
|
Dominari Securities LLC Receives Milestone Approval as a Nasdaq Limited Underwriting Member
- NEW YORK CITY, NY / ACCESSWIRE / August 13, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"), has been approved as a Limited Underwriting Member of the Nasdaq Stock Market. This approval enables Dominari to act as a principal underwriter under Nasdaq Listing Rule 5210(m).
- 08/13/2024
|
Dominari Securities LLC Continues Expansion of Its Capital Market Group with Senior Hires
- Adds Capital Markets Expert and Best-Selling Author, Steve Kann and Strategic and Financial Advisory Veteran, Andre Peschong, as Managing Directors NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company") today noted that its wholly-owned subsidiary, Dominari Securities LLC, announced that it has further expanded its practice with the addition of Steve Kann and Andre Peschong as Managing Directors. Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "The breadth and depth of experience that Steve and Andre bring to the team will be extremely valuable in helping us to realize our strategic vision of developing Dominari into a full-serve, diversified financial services firm.
- 04/17/2024
|
Dominari Securities Appoints 30 Year Financial Industry Expert to Manage Operations and Compliance
- Eric Newman Appointed as Executive Vice President NEW YORK , March 15, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed financial industry veteran, Eric Newman, to the role of Executive Vice President of Dominari Securities enriching the firm's investment banking expertise and bolstering its brokerage operations. Mr. Newman reports directly to CEO Kyle Wool and is responsible for managing the day-to-day aspects of the firm's broker-dealer operations, advising executive leadership on key corporate planning issues and managing the implementation of the firm's business and strategic plans.
- 03/15/2024
|
Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive
- Dr. Cosme Ordoñez Appointed Head of Investment Banking NEW YORK , March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed Dr. Cosme Ordoñez to the role of Head of Investment Banking, Investment Banking Principal and bolstering the firm's coverage in the healthcare sector. Dr. Ordoñez has more than 20 years of investment banking and healthcare experience.
- 03/12/2024
|
Dominari Securities LLC Continues to Add Depth with Three New Hires
- Adds High Producing Private Equity Team of Larry Cohen and John Russo and Seasoned Specialty Finance Executive Michael Siek NEW YORK , March 7, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has further expanded its practice to include the high-producing private equity investment banking team of Larry Cohen and John Russo and senior manager and director Michael Siek. The three executives join Dominari Securities from AegisStern Ventures.
- 03/07/2024
|
Dominari Securities LLC Welcomes Wealth Management Team Gotham Equities
- Adds David Reimer, Peter Sandler and team of five experienced wealth management professionals NEW YORK , March 6, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has expanded its wealth management team to include Mr. David Reimer, CEO of Gotham Equities; Wealth Advisor, Mr.
- 03/06/2024
|
Dominari Securities LLC Welcomes Another Wealth Management Team
- Adds seasoned Wealth Advisors, Michael Schiavello and Billy Takos, and team of 12 experienced wealth advisors NEW YORK , March 5, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has further expanded its wealth management practice to include a team of 12 seasoned wealth advisors led by Mr. Michael Schiavello and Mr.
- 03/05/2024
|
Dominari Securities LLC Serves as Lead Underwriter for $5 Million Initial Public Offering for Unusual Machines
- NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, acted as lead underwriter to Unusual Machines (NYSE American: UMAC), an emerging leader in first-person view (FPV) drone technology, in an initial public offering ("Offering") of 1,250,000 shares of common stock at a public offering price of $4.00 per share for gross proceeds of $5.0 million before deducting underwriting discounts and other related expenses. The shares of Unusual Machines began trading on the NYSE American on February 14, 2024, under the ticker symbol "UMAC".
- 02/15/2024
|
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
- AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company. The post Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
- 06/07/2022
|
Aikido Pharma (AIKI) Stock Price: 1-For-17 Reverse Split Goes Into Effect
- A 1 for 17 reverse stock split of AIkido Pharma, Inc. (NASDAQ: AIKI) has gone into effect. These are the details.
- 06/07/2022
|
Trending Penny Stocks to Watch After Holiday Season
- Which penny stocks are you watching right now? The post Trending Penny Stocks to Watch After Holiday Season appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/02/2022
|
5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes
- There are so many traders looking for the best penny stocks 2021… The post 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/01/2021
|
Best Penny Stocks to Buy Right Now? 3 to Watch This Month
- If you're making a penny stocks watchlist in November, here's three you should check out The post Best Penny Stocks to Buy Right Now? 3 to Watch This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/01/2021
|
Best Penny Stocks to Buy in November? 3 You Need to Know About
- Are these penny stocks on your November watchlist? The post Best Penny Stocks to Buy in November?
- 10/30/2021
|
Trump-Linked SPAC Has Traders Also Focused On These 6 Stocks
- The second half of October has been one of the most active periods for the stock market in quite some time. Not only did the major indexes, including the SPDR S&P 500 ETF (NYSE: SPY) and SPDR Dow Jones Industrial Average ETF Trust (NYSE: DIA) hit fresh, all-time highs, retail traders, are finally getting their fill of volatile small-caps and short squeeze stocks.
- 10/22/2021
|
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
- Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/11/2021
|
AIkido Pharma Trading 30% Below Cash Value Despite Positive Indications
- Photo by Joshua Mayo on Unsplash Biotechnology development company AIkido Pharma Inc. (NASDAQ: AIKI) recently released its 1st-quarter report, which revealed the strongest balance sheet in the company's history with approximately $102 million in cash and cash equivalents.
- 10/06/2021
|
Top Penny Stocks to Watch As October Gets Off to a Bullish Start
- October is getting off to a great start for penny stocks, here's three to watch The post Top Penny Stocks to Watch As October Gets Off to a Bullish Start appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/01/2021
|
5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally
- Best penny stocks to watch under $1? The post 5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/28/2021
|
AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd
- NEW YORK, Sept. 28, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an equity interest in Tevva Motors Ltd, an electric truck producer with range extended vehicles on the road now.
- 09/28/2021
|
Are Biotech Penny Stocks Worth Buying? Check These 3 Out
- Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/20/2021
|
AIkido Pharma Secures Interest in Growing Tele-health Company
- NEW YORK, Sept. 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an early equity interest in tele-health company, Kerna Health (https://kernahealth.com).
- 09/20/2021
|
AIkido Provides Update on Use of Machine Learning in Drug Development Program
- NEW YORK, Aug. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore School of Medicine. The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.
- 08/06/2021
|
Notice of Allowance Issued for Central Nervous System Peptide Technology
- NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125.
- 07/27/2021
|
AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland
- NEW YORK, July 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine. The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.
- 07/16/2021
|
AIkido Pharma to Attend the Alzheimer's Association International Conference
- NEW YORK, July 13, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will attend the Alzheimer's Association International Conference in Denver, July 26-30, 2021. ("AAIC 2021") The AAIC is the largest and most influential international meeting dedicated to advancing dementia science.
- 07/13/2021
|
AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease
- NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease. The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.
- 06/23/2021
|
AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591
- NEW YORK, June 4, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021. The poster presentation of the data was by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member.
- 06/04/2021
|
AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash
- New York, New York--(Newsfile Corp. - May 20, 2021) - PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals (NASDAQ: AIKI), according to the company's Q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide therapy (PRRT) with notable insider buying in the open market displaying his strong belief in the Company's prospects.Developed by Weill Cornell Medicine...
- 05/20/2021
|
AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting
- NEW YORK, May 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting June 4, 2021. The presentation of the data will be by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member.
- 05/20/2021
|
7 Reddit Penny Stocks Promising to Cure Cancer
- These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.
- 05/14/2021
|
AIKI's Near Term Catalyst Approaching this Quarter with Strong Cash Balance Sheet for Strategic Initiatives
- New York, New York--(Newsfile Corp. - May 13, 2021) - PCG Digital -- Things seem to be heating up for (NASDAQ: AIKI) with a near term potential catalyst quickly approaching this quarter and several others planned throughout the remainder of the year. Management has been filing form 4s showing open market buying which typically signals strong faith in the company and signifies how undervalued they believe the stock may be at these levels. Speaking of...
- 05/13/2021
|
AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update
- NEW YORK, May 11, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Anthony Hayes, CEO of AIkido Pharma, stated, "With testing data expected in this current quarter, we are excited about the results and the advancement of our technologies.
- 05/11/2021
|
Top Biotech Penny Stocks on Reddit? Check These 3 Out
- Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?
- 04/30/2021
|
4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now
- Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/25/2021
|
Biotech Penny Stocks To Buy? 3 to Watch Under $5
- Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/23/2021
|
AIkido Pharma Notes Advancement in Radiopharmaceutical Research
- NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.
- 04/16/2021
|
AIkido Pharma Provides Business Update
- NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning.
- 04/05/2021
|
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
- NEW YORK, Feb. 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional 7,030,927 shares of...
- 02/23/2021
|
Aikido Pharma Slumps On $75M Upsized Equity Offering Issued At 25% Discount
- Aikido Pharma Inc (NASDAQ: AIKI) has increased the size of the previously announced public offering to 46.8 million shares at $1.60 per share, with gross proceeds of $75 million. The previous offering included 6.25 million shares for gross proceeds of a mere $10 million.
- 02/17/2021
|
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
- NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 46,875,000 shares...
- 02/16/2021
|
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
- NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000...
- 02/16/2021
|
Why Change Healthcare, Isoray And Alkido Are Moving Today
- Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido Pharma is engaged in the development of small-molecule anti-cancer therapeutics.
- 01/06/2021
|
Aikido Pharma News: Why AIKI Stock Is Soaring Today
- Shares of AIKI stock are skyrocketing after Aikido Pharma announced a new patent agreement for the use of psilocybin for cancer treatments. The post Aikido Pharma News: Why AIKI Stock Is Soaring Today appeared first on InvestorPlace.
- 01/06/2021
|
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
- NEW YORK, Dec. 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer. Pancreatic ductal...
- 12/09/2020
|
AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting
- NEW YORK, Nov. 20, 2020 /PRNewswire/ -- AIkido Pharma Inc. (the "Company" or "AIkido") (NASDAQ: AIKI) today announced the results from the virtual 2020 Annual Meeting of Stockholders (the "Meeting") held on November 17, 2020 (the "Meeting"). All proposals that were presented to the...
- 11/20/2020
|
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
- NEW YORK, Oct. 28, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer,...
- 10/28/2020
|
12 Healthcare Stocks Moving In Friday's After-Market Session
- Gainers
InVivo Therapeutics Hldg (NASDAQ:NVIV) shares rose 11.11% to $1.5 during Friday's after-market session. InVivo Therapeutics Hldg's trading volume hit 1.4K shares...
- 10/16/2020
|
Stock’s Volume Buzz: AIkido Pharma Inc. (NASDAQ:AIKI), Canadian Natural Resources Limited (NYSE:CNQ) - Stocks Equity
- AIkido Pharma Inc. (NASDAQ:AIKI) with the stream of -11.24% also noticed, India Canadian Natural Resources Limited (NYSE:CNQ) encountered a rapid change of -0.77% in the last hour of Friday’s trading …
- 09/14/2020
|
AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido has been granted an exclusive option to license the drug ("Option") pending the results of the study.
- 08/18/2020
|
AIkido Pharma Inc. to Present at The LD 500 Virtual Conference
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 11:20 a.m. ET. Anthony Hayes, CEO of AIkido Pharma Inc. will be presenting to a live audience.
- 08/14/2020
|
Option for Treatment for Coronavirus Extended
- AIkido Pharma Inc. (Nasdaq: AIKI) today announced it has extended its previously disclosed exclusive option agreement ("Option") with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 "Methods of Treating Coronavirus Infection." The present invention provides methods for treating a coronavirus infection. The initial Option for Treatment of Coronavirus was previously disclosed on March 6, 2020. The Option has been extended until December 2, 2020. All other terms and conditions of the original Option agreement remain in full force and effect.
- 08/11/2020
|
LD Micro Announces Preliminary List of Presenters for the LD 500
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on July 31, 2020, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at or above $1.00 for ten consecutive business days.
- 08/03/2020
|
AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License Agreement with the University of Maryland, Baltimore ("UMB"), covering certain antiviral compounds discovered by UMB.
- 07/09/2020
|
AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced an update to its machine learning driven pancreatic cancer research.
- 06/26/2020
|
AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University
- AIkido Pharma Inc. (Nasdaq: AIKI) today announced publication of a paper: The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C by Peter M. Alexander, Gregory L. Kucera, Kristin M. Pladna and Timothy S. Pardee in the July 2020 issue of Translational Oncology. The paper documents the results from the company's sponsored research at Wake Forest University.
- 05/28/2020
|
AIkido Pharma Inc. Announces Distribution of Hoth Dividend
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the distribution of the previously announced Hoth Therapeutics, Inc. ("Hoth") stock dividend, has commenced and stockholders will receive their dividend in the next few days by mail or electronic deposit.
- 05/19/2020
|
AIkido Pharma Inc. Provides Update on Distribution Date for Hoth Dividend Distribution
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Hoth Therapeutics Inc. registered the stock to be distributed on April 3 2020.(https://www.sec.gov/Archives/edgar/data/1711786/000121390020008546/ea120229-s1_hoththerape.htm). The registration was declared effective and the Prospectus was filed on May 7, 2020.(https://www.sec.gov/Archives/edgar/data/1711786/000121390020011222/ea121442-424b3_hoththerap.htm). We thank Hoth for their assistance.
- 05/08/2020
|
AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement with Cogia Biotech LTD
- AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research. Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development. Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development. Cogia's existing clients include many international companies, including international pharmaceutical companies.
- 05/06/2020
|
AIkido Pharma Inc. Provides Update on Anticipated Distribution Date for Hoth Dividend Distribution
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the distribution date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") will not be taking place today, May 4, 2020, because of the requirement that the shares be registered prior to distribution. AIkido will provide a distribution date for the distribution of the shares promptly once the registration statement is declared effective. The Company is waiting on ("Hoth") to seek acceleration of the registration statement, which is a prerequisite for distribution. We hope for this to be done shortly and will update shareholders as soon as possible. The record date has not changed and individuals who were shareholders at 4pm on April 30th, 2020 will be receiving the dividend. No further action is required.
- 05/04/2020
|
Notice of Record Date of Hoth Distribution
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced a reminder to the Company's stockholders that today, April 30, 2020, is the record date for the previously announced distribution to our stockholders of shares of common stock of Hoth Therapeutics, Inc. ("Hoth"). Each stockholder of the Company, as of 4:00 p.m. Eastern Time on April 30, 2020, is entitled to receive one (1) share of Hoth common stock for every five hundred (500) shares of AIkido common stock held. The original ratio of seventy (70) shares was changed to reflect the increase in the number of Company shares issued and outstanding, as of today's record date. The Company expects to distribute the shares of Hoth common stock on May 4, 2020.
- 04/30/2020
|
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech's Ocrevus on the Rise, Biogen's Tecfidera Declines, and Teva's Copaxone Remains Strong, According to Spherix Global Insights
- Genentech's Ocrevus, Teva's Copaxone, and Biogen's Tecfidera score the top three share positions among patients who recently switched to a different disease-modifying therapy (DMT). The diverse clinical profiles of the current share leaders underscore the importance of each DMT class in this
- 04/30/2020
|
AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on April 13, 2020, the Company executed a Master License Agreement (the "License Agreement") with the University of Maryland, Baltimore ("UMB"). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.
- 04/21/2020
|
AIkido Pharma Inc. Sets Record Date for Hoth Distribution
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") is April 30, 2020, and the Company is currently working to determine the date of distribution.
- 04/20/2020
|
AIkido Pharma Inc. Announces Closing of $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), a technology development company committed to the fostering of innovative ideas, announced today the closing of its previously announced registered direct offering with several institutional and accredited investors of 14,000,000 shares of its common stock at a purchase price of $1.00 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled $14.0 million, before deducting placement agent fees and other offering expenses.
- 04/15/2020
|
AIkido Pharma Inc. Announces $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 14,000,000 shares of AIkido's common stock, at a purchase price of $1.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.
- 04/14/2020
|
AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus
- AIkido Pharma Incorporated (Nasdaq: AIKI) today announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-COV (coronavirus), MERS-COV, Ebolavirus and Marburg virus.
- 04/14/2020
|
17 Healthcare Stocks Moving In Friday's Pre-Market Session
- Gainers
• electroCore, Inc. (NASDAQ:ECOR) shares rose 108.98% to $1.56 during Friday's pre-market session. The most recent rating by H.C. Wainwright, on Mar 24, is at Buy...
- 04/03/2020
|
Bull Flag Pattern: What It Is and Trading Strategies for 2020
- The bull flag pattern is a great addition to any trader’s toolbox. It can be a simple way to enter on breakouts with lower risk.
- 04/02/2020
|
The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NASDAQ: FTSV) * Ra Pharmaceuticals Inc (NASDAQ: RARX) * Quidel Corporation (NASDAQ: QDEL)Down In
- 04/01/2020
|
AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution
- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date and distribution date to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") will be deferred because of the requirement that the shares be registered prior to distribution. AIkido will provide a record date and distribution date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update to shareholders in two weeks on the status of this matter.
- 03/27/2020
|
AIkido Issues Shareholder Update on COVID-19, Dividend, And Path Forward
- AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update onto shareholders as follows:
- 03/26/2020
|
AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets
- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced that its Board of Directors (the "Board") has acted to preserve and protect the Company's valuable income tax net operating loss carryforwards ("NOLs") by adopting a stockholder rights plan in the form of a Section 382 Rights Agreement, dated as of March 23, 2020, by and between the Company and VStock Transfer LLC (the "Stockholder Rights Plan").
- 03/24/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
Shareholder Update from AIkido Pharma Incorporated on Coronavirus Option
- AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update on the recently announced Coronavirus technology optioned by the Company.
- 03/18/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
Stocks That Hit 52-Week Highs On Monday
- On Monday, 10 companies reached new 52-week highs.
Points of Interest:
Clorox (NYSE: CLX) was the biggest company by market cap to set a new 52-week high.
The company...
- 03/09/2020
|
Mid-Afternoon Market Update: Dow Tumbles 8%; AIM ImmunoTech Shares Spikes Higher
- Toward the end of trading Monday, the Dow traded down 8% to 23794.55 while the NASDAQ fell 6.95% to 7,979.78. The S&P also fell, dropping 7.71% to 2,743.27. Coronavirus cases...
- 03/09/2020
|
Mid-Day Market Update: Dow Falls 1400 Points; Matador Resources Shares Plunge
- Midway through trading Monday, the Dow traded down 5.43% to 24,461 while the NASDAQ fell 4.35% to 8,202.44. The S&P also fell, dropping 5.03% to 2822.74. Coronavirus cases...
- 03/09/2020
|
101 Stocks Moving In Monday's Mid-Day Session
- Gainers
Spherix Incorporated (NASDAQ: SPEX) shares jumped 139% to $3.92 after jumping 131% on Friday.
AIM ImmunoTech Inc. (NYSE: AIM) shares jumped 63.1% to $3.43 amid the...
- 03/09/2020
|
Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection
- Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the...
- 03/06/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
WLL, SPEX, CODX and AIM among midday movers
- Gainers: iBio (NYSEMKT:IBIO) +131%.GAIN Capital Holdings (NYSE:GCAP) +66%.Vaxart (NASDAQ:VXRT) +57%.Co-Diagnostics (NASDAQ:CODX) +55%.Vir Biotechnology (NASDAQ:VIR) +51%.Allied Healthcare Products (NA
- 02/27/2020
|
ABEV, PLAN among premarket losers
- Anaplan (NYSE:PLAN) -29% despite Q4 beat.Continental Resources (NYSE:CLR) -26% on Q4 earnings.Nutanix (NASDAQ:NTNX) -20% on Q2 earnings.Virgin Galactic Holdings (NYSE:SPCE) -18% after pair of Wall Str
- 02/27/2020
|
TOL, SDC among premarket losers
- SmileDirectClub (NASDAQ:SDC) -24% on Q4 earnings.Spherix (NASDAQ:SPEX) -22%.Fossil Group (NASDAQ:FOSL) -20% on Q4 earnings.Menlo Therapeutics (NASDAQ:MNLO) -19% after chronic pruritus Phase 2 trial fa
- 02/26/2020
|
